Increased HRD score in cisplatin resistant penile cancer cells

Background/Introduction Penile cancer is a rare disease in demand for new therapeutic options. Frequently used combination chemotherapy with 5 fluorouracil (5-FU) and cisplatin (CDDP) in patients with metastatic penile cancer mostly results in the development of acquired drug resistance. Availabilit...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	BMC cancer Ročník 22; číslo 1; s. 1352 - 14
Hlavní autoři:	Winkelmann, Ria, Bankov, Katrin, Döring, Claudia, Cinatl, Jaroslav, Grothe, Sebastian, Rothweiler, Florian, Michaelis, Martin, Schmitt, Christina, Wild, Peter J., Demes, Melanie, Cinatl, Jindrich, Vallo, Stefan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	London BioMed Central 23.12.2022 BioMed Central Ltd BMC
Témata:	Antineoplastic Combined Chemotherapy Protocols - pharmacology Biomedical and Life Sciences Biomedicine Cancer Research Care and treatment Cell Line, Tumor Cell lines Chemoresistance Cisplatin Cisplatin - pharmacology Cisplatin - therapeutic use Development and progression Diagnosis Dosage and administration Drug resistance Drug Resistance, Neoplasm - genetics Fluorouracil - pharmacology Fluorouracil - therapeutic use Health Promotion and Disease Prevention Homologous recombination deficiency Humans Male Medicine/Public Health Oncology Patient outcomes Penile cancer Penile carcinomas Penile Neoplasms - drug therapy Risk factors Surgical Oncology Germany Penile carcinomas Homologous recombination deficiency Cell lines Chemoresistance
ISSN:	1471-2407, 1471-2407
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!